Human IFN-γ1b
Synonyms: IFN-γ

IFN-γ stands for interferon γ. Human IFN-γ is a recombinant protein optimized for use in cell culture, differentiation studies, and functional assays.

Select a quality grade:
Select a size:
Other sizes
Specifications for Human IFN-γ1b
Overview

IFN-γ stands for interferon γ. Human IFN-γ is a recombinant protein optimized for use in cell culture, differentiation studies, and functional assays.

Applications

Human IFN-γ1b can be used for a variety of applications, including:

  • Stimulation of monocytes, macrophages, and microglia.
  • In vitro maturation of Mo-DCs.
  • Apoptosis and cell growth inhibition assays.
  • Adhesion and migration assays.
Alternative names

IFN-γ

Detailed product information

Biological activity

Determination method
Proliferation of HT-29 cells (NIAID Gxg01-902-535)
Research grade
≥ 1×106 IU/mg
Premium grade
≥ 2×106 IU/mg (Typical activity 5×107 IU/mg)
We measure the biological activity of each batch of MACS Premium-Grade Cytokines and state the results in the Certificate of Analysis (CoA). Based on the lot-specific activity, exact doses of active cytokine can be applied to cell culture experiments. This allows for reproducible cell culture conditions without the need for time-consuming lot-to-lot testing.
Background information

IFN-γ, the only type II interferon, possesses potent anti-viral activity and immunoregulatory properties. It is structurally unrelated to the type I interferons and binds to a different receptor expressed by most immune cells. IFN-γ is produced predominantly by NK cells and T cells. IFN-γ enhances NK cell and macrophage activity and regulates B cell functions, like immunglobulin production and class switching. In addition, IFN-γ orchestrates leukocyte attraction and directs growth, maturation, and differentiation of many cell types. The activity of human IFN-γ is species-specific.

Quality description

Research-grade cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.

Premium-grade cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific activities are stated in the Certificate of Analysis (www. miltenyibiotec.com/certificates).

Product data and images for Human IFN-γ1b
Figure 1

Human IFN-γ1b activity assay. The biological activity of Human IFN-γ1b is determined by inhibition assay using HT-29 cells. Activity of Human IFN-γ1b, premium grade (red line) was compared to another commercially available product (black line).

Figure 2

SDS-PAGE of Human IFN-γ1b, premium grade under reducing (R) and non-reducing (NR) conditions.

Figure 3

Human IFN-γ1b biological activity. Activity of Human IFN-γ1b, premium grade, (red bar) was compared to another commercially available product (black bar).

Figure 4

Mass spectrometry analysis (ESI-MS) of Human IFN-γ1b, premium grade. The peak corresponds to the calculated molecular mass of 16334 Da.

Resources for Human IFN-γ1b
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for Human IFN-γ1b
Publications
  1. Fan, X.-Y. et al. (2017) All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion. Sci Rep 7 (1): 16481
  2. Leuci, V. et al. (2018) CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology 7 (5): e1423167
  3. Graciotti, M. et al. (2020) Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines. Vaccines (Basel) 8 (2): 271
  4. Mesiano, G. et al. (2018) Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. Oncoimmunology 7 (11): e1465161
  5. Ding, X. et al. (2015) Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med. 13: 158
  6. Jones, S. P. et al. (2015) Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLoS One 10 (6): e0131389
  7. Wong, V. L. et al. (1989) Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int. J. Cancer 43: 526-530
  8. Niu, C. et al. (2015) In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells. BMC Immunol. 16: 61